Skip to main content
. Author manuscript; available in PMC: 2024 Apr 17.
Published in final edited form as: Sci Transl Med. 2023 Apr 5;15(690):eadd5318. doi: 10.1126/scitranslmed.add5318

Fig. 4. Bcl-2i plus TBI extends renal allograft survival in combined CKBMT.

Fig. 4.

(A) Renal allograft survival rates. Renal allograft survival (left) and rejection/DSA-free survival (right) were measured in groups A to D (n = 8, group A; n = 5, group B; n = 6, group C; n = 2, group D). Kaplan-Meier analysis was used to estimate survival time distributions, and Mantel-Cox log-rank test was used to compare between-group differences.*P < 0.05 and **P < 0.01. (B) Serum creatinine after CKBMT. Serum creatinine (milligrams per deciliter) was measured longitudinally after CKBMT (AR, acute rejection; CR, chronic rejection; UO, urinary obstruction). CR* indicates a recipient euthanized on day 837 because of extensive proteinuria despite normal serum creatinine (n = 8, group A; n = 5, group B; n = 6, group C; n = 2, group D). (C to F) Representative histopathologic findings in groups A to D. (C) A day 837 renal allograft biopsy from a group A recipient shows extensive transplant glomerulopathy with glomerulitis and peritubular capillaritis consistent with chronic active antibody-mediated rejection. H&E, 40×; scale bar, 50 μm. (D) A day 112 renal allograft biopsy from a group B recipient shows acute cellular rejection with transmural arteritis without C4d or DSA [Banff T cell–mediated rejection (TCMR) type III]. PAS, 10×; scale bar, 200 μm. (E) A day 804 allograft biopsy from a group C recipient shows no evidence of rejection. PAS, 20×; scale bar, 100 μm. (F) Shown is an image of the kidney from an autopsy (day 120) of a goup D recipient. The image shows evidence of Banff TCMR type III. H&E, 20×; scale bar, 100 μm. (G) Three group C recipients underwent skin transplantation 1 year after CKBMT from the kidney donor and third party (3P) donors. A representative photo taken at 3 weeks shows specific acceptance of the skin graft from the bone marrow and kidney donor (donor) and rejection of the 3P skin.